The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | Insights from BTOG 2024: advancements in TNM staging, systematic staging, & immunotherapy strategies
Thomas Newsom-Davis, Chelsea and Westminster Hospital NHS Foundation Trust, discusses a session he chaired at the BTOG 2024 congress featuring four enlightening talks. Prof. Paul Van Schill introduced the 9th edition of tumour-node-metastasis (TNM) staging classification, highlighting its application in non-small cell lung cancer (NSCLC), thymic tumors, and mesothelioma to refine prognosis by categorizing tumors into smaller groups. Dr Fiona MacDonald discussed systematic staging using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), emphasizing its impact on treatment planning for locally advanced disease. Prof. Matthias Guggenberger explored the role of stereotactic radiotherapy for bone metastases, emphasizing its potential in oligometastatic disease and as a palliative treatment. Prof. Mary O’Brien presented the Phase II REFINE study (NCT04913025), investigating de-escalation strategies for immunotherapy frequency and intensity in cancers, aiming to optimize patient care and resource utilization. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
